Innovative capabilities and strategic alliances: Who is gaining what in the pharmaceutical industry?
PDF

Keywords

strategic alliance
innovative capability

Abstract

There have been several respected studies, from a capability-based perspective, pointing to the emergence of a new division of innovative labour in the pharmaceutical industry over the past decades. We still, however, miss empirical evidence relative to the implications of collaborative arrangements, like strategic alliances, for the innovative capabilities of companies involved in such collaborative arrangements. Drawing on a scrutiny of specialised databases (Galé, Dialog, and Business & Industry) covering the 1993–2003 period, this paper examines the entry and exit composition of innovative capabilities of 25 pharmaceutical companies' capabilities involved in such alliances. They are organised in three groups: (i) large pharmaceutical companies ('big-pharma'); (ii) large bio-pharmaceutical companies ('bio-pharma'); and (iii) small and research-intensive companies. The evidence shows the extent to which each of these three types companies, particularly large companies, benefit from these alliances in terms of absorption of strategic pieces of innovative capabilities. Such type of evidence is important to provide researchers, corporate managers, and policy makers with a concrete notion of some features of the nature of such division of innovative labour that occurs and the actual changes going on in the structure and organisation of innovative activities in the pharmaceutical industry.

https://doi.org/10.5912/jcb213
PDF

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.